Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC looks for support on central nanotech regulatory drafting framework

This article was originally published in Clinica

Executive Summary

The European Commission is calling for responses from interested stakeholders, including the medical technology industry, to the opinion on nanotechnologies that has just been adopted by independent experts at its scientific committee on emerging and newly identified health risks (SCENIHR). Speaking at a conference on nanotechnology held by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on October 27, Didier Bouis, the person in charge of looking into the regulation of all areas of nanotechnology within the European Commission's Directorate General for Enterprise and Industry, explained that the EU is still at very preliminary stages of considering how nanotechnology products, including nanomedicines, should be regulated.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel